Market Overview

UPDATE: JP Morgan Maintains Rigel Pharmaceuticals at Overweight Post 4Q Results

Related RIGL
Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know
3 Covered Call Trades For A Quick Hit (Seeking Alpha)

In a report published Tuesday, JP Morgan maintained an Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and maintained its $10 price target.

JP Morgan reported that, “Our recommendation is primarily based on the potential for RIGL's lead asset, fostamatinib, in rheumatoid arthritis (RA). RA represents a huge worldwide annual market of ~$13B and growing, and we believe fostamatinib could emerge as a meaningful player in this space. We believe that Phase 2b TASKi2 data, as well as RIGL's partnership with AstraZeneca, provide important validation for the drug and are optimistic that the Phase 3 OSKIRA program will be successful (Phase 3 readout is expected in 1H13). In addition, we believe that RIGL is well positioned financially with a healthy balance sheet (as well as a partner that is paying for fostamatinib's Phase 3 program) and that the company's early-stage pipeline represents close to a free call option at current valuation."

Rigel Pharmaceuticals' shares closes at $6.82 on Monday.

Latest Ratings for RIGL

Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight
May 2016JefferiesMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Analyst Ratings


Related Articles (RIGL)

View Comments and Join the Discussion!